Par Believes It Holds 180-Day Exclusivity For AndroGel Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson also maintains it holds first-to-file exclusivity for a generic version of Solvay’s testosterone replacement gel, Par says. Solvay’s patent infringement suit against Par is expected to go to trial in the fourth quarter of 2005.